Tuesday February 26, 2008 9:15 am ET
MOUNTAINSIDE, N.J., Feb. 26 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Pink Sheets: NHGI) today announced that its President Michael Cohen will present a Keynote Address, "A New Collaboration Model for Government Agencies, Academic Institutions and Development Stage Biotech Companies," at the Inaugural meeting of The Stem Cell Partnering Series: Fostering Business Collaborations & Careers in Stem Cell Science, February 28- 29, 2008, to be held at the University of California San Diego.
National Stem Cell President, Michael Cohen, stated, "I am pleased to participate in this event which has focused much needed attention to two critically important issues facing the stem cell / Regenerative Medicine industry: the need for increasing and improving strategic collaborations among the key stakeholders namely, development stage biotech companies, academic Institutions and government agencies, together with the attendant need to develop and recruit trained scientific personnel to meet both current and future industrial demands. Failure to address these issues rapidly and effectively within the U.S. risks the significant loss of intellectual property research and development and value to industrial sectors abroad."
The Stem Cell Partnering Series is a not-for-profit organization that actively supports the development and sustainability of the stem cell industry by fostering business collaborations and career development.
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.
"Safe Harbor Statement"
Under The Private Securities Litigation Reform Act of 1995: The
statements in the press release that relate to the company's expectations
with regard to the future impact on the company's results from new products
in development are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The results anticipated
by any or all of these forward-looking statements may not occur. The
Company undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof, or to reflect the occurrence
of unanticipated events or changes in the Company's plans or expectations.
|SOURCE National Stem Cell Holding, Inc.|
Copyright©2008 PR Newswire.
All rights reserved